This preprint is under consideration at Alzheimer's Research and Therapy. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Agathe Vrillon
APHP: Assistance Publique - Hopitaux de Paris
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0761-7885
License:
This work is licensed under a CC BY 4.0 License. Read Full License
BACKGROUND
There is limited evidence on the characteristics and outcome of patients with dementia hospitalized for novel coronavirus infection (COVID-19).
METHOD
We conducted a prospective study in 2 gerontologic Covid Units in Paris, France, from March 14th 2020 to May 7th 2020. Patients with dementia hospitalized for confirmed COVID-19 infection were systematically enrolled. A binary logistic regression analysis was performed to identify factors associated with mortality at 21 days.
RESULTS
We included 125 patients. Median age was 86 (IQI 82-90); 59.4% were female. Most common causes of dementia were Alzheimer’s disease, mixed dementia and vascular dementia. 67.2% had ≥2 comorbidities; 40.2% lived in a long-term care facility. The most common symptoms at COVID-19 onset were confusion and delirium (82.4%), asthenia (76.8%) and fever (72.8%) before polypnea (51.2%) and desaturation (50.4%). Falls were frequent at the initial phase of the disease (35.2%). The fatality rate at 21 days was 22.4%. Chronic kidney disease and CRP at admission were independent factors of death. Persisting confusion, mood and behavioral disorders were observed in survivors (19.2%).
CONCLUSION
COVID-19 in demented individuals is associated with severe outcome in SARS-CoV-2 infection and is characterized by specific clinical features and complications, with confusion and delirium at the forefront. COVID‐19 testing should be considered in front of any significant change from baseline.
Keywords
COVID-19, SARS-Cov2, dementia, mortality, prognostic factors
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version (no preprint)
Posted 24 Mar, 2021
Reviewer #2 agreed
On 24 Mar, 2021
Review #2 received
Received 24 Mar, 2021
Editor assigned
On 21 Mar, 2021
Reviewers invited
Invitations sent on 21 Mar, 2021
Reviewer #1 agreed
On 21 Mar, 2021
Review #1 received
Received 21 Mar, 2021
Submission checks complete
On 21 Mar, 2021
Editor invited
On 21 Mar, 2021
This version was not preprinted
Version 1
Posted 18 Feb, 2021
No community comments so far
Editorial decision: Major Revision
On 06 Mar, 2021
Review #1 received
Received 22 Feb, 2021
Review #2 received
Received 22 Feb, 2021
Reviewer #2 agreed
On 18 Feb, 2021
Reviews received
Received 18 Feb, 2021
Reviewer #1 agreed
On 18 Feb, 2021
Reviewers invited
Invitations sent on 15 Feb, 2021
Editor assigned
On 07 Feb, 2021
Submission checks complete
On 07 Feb, 2021
Editor invited
On 07 Feb, 2021
First submitted
On 03 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cognitive Neuroscience
Learn more about our company.
This preprint is under consideration at Alzheimer's Research and Therapy. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Agathe Vrillon
APHP: Assistance Publique - Hopitaux de Paris
Corresponding Author
ORCiD: https://orcid.org/0000-0002-0761-7885
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version (no preprint)
Posted 24 Mar, 2021
Reviewer #2 agreed
On 24 Mar, 2021
Review #2 received
Received 24 Mar, 2021
Editor assigned
On 21 Mar, 2021
Reviewers invited
Invitations sent on 21 Mar, 2021
Reviewer #1 agreed
On 21 Mar, 2021
Review #1 received
Received 21 Mar, 2021
Submission checks complete
On 21 Mar, 2021
Editor invited
On 21 Mar, 2021
This version was not preprinted
Version 1
Posted 18 Feb, 2021
No community comments so far
Editorial decision: Major Revision
On 06 Mar, 2021
Review #1 received
Received 22 Feb, 2021
Review #2 received
Received 22 Feb, 2021
Reviewer #2 agreed
On 18 Feb, 2021
Reviews received
Received 18 Feb, 2021
Reviewer #1 agreed
On 18 Feb, 2021
Reviewers invited
Invitations sent on 15 Feb, 2021
Editor assigned
On 07 Feb, 2021
Submission checks complete
On 07 Feb, 2021
Editor invited
On 07 Feb, 2021
First submitted
On 03 Feb, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cognitive Neuroscience
License:
This work is licensed under a CC BY 4.0 License. Read Full License
BACKGROUND
There is limited evidence on the characteristics and outcome of patients with dementia hospitalized for novel coronavirus infection (COVID-19).
METHOD
We conducted a prospective study in 2 gerontologic Covid Units in Paris, France, from March 14th 2020 to May 7th 2020. Patients with dementia hospitalized for confirmed COVID-19 infection were systematically enrolled. A binary logistic regression analysis was performed to identify factors associated with mortality at 21 days.
RESULTS
We included 125 patients. Median age was 86 (IQI 82-90); 59.4% were female. Most common causes of dementia were Alzheimer’s disease, mixed dementia and vascular dementia. 67.2% had ≥2 comorbidities; 40.2% lived in a long-term care facility. The most common symptoms at COVID-19 onset were confusion and delirium (82.4%), asthenia (76.8%) and fever (72.8%) before polypnea (51.2%) and desaturation (50.4%). Falls were frequent at the initial phase of the disease (35.2%). The fatality rate at 21 days was 22.4%. Chronic kidney disease and CRP at admission were independent factors of death. Persisting confusion, mood and behavioral disorders were observed in survivors (19.2%).
CONCLUSION
COVID-19 in demented individuals is associated with severe outcome in SARS-CoV-2 infection and is characterized by specific clinical features and complications, with confusion and delirium at the forefront. COVID‐19 testing should be considered in front of any significant change from baseline.
Loading...